Table 4.

Summary of non-inferiority of live SARS-CoV-2 neutralizing antibody seroconversion rate (SCR) between adolescents (12–<18 years) and young adults (20–30 years) who received MVC-COV1901.

Per protocol set (PPS) Visit 6 (Day 57)	Adolescents of MVC-COV1901 (N = 334)	Young Adults of MVC-COV1901 (N = 210)	Difference adolescent/young adults	P-value
SCR, n (%)	334 (100%)	210 (100%)	−0.0%	N/A
95% CIa	98.90–100.00%	98.26–100.00%	−0.00% to 0.00%

^aCI calculated using a normal approximation for the binomial proportion of #.